BCL2 and hematologic disorder: Nevertheless, the role of the Akt signaling pathway possibly by upregulation of non-Bcl-2 antiapoptotic proteins such as MCL-1 and Bcl-XL in the development of venetoclax resistance has been confirmed in hematologic malignancies [83–85].